Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Amino acid or derivative
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 5962
Molecular formula: C6H14N2O2
IUPAC: (2S)-2,6-diaminohexanoic acid
Source: PC-LYSINE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Essential amino acid used in protein synthesis; not equivalent to tripeptide KPV despite sharing a residue/name.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context
Nutrition/empirical supplement uses including herpes prevention; appears as a blend ingredient.
Human evidence
A small older trial with 52 completers reported a favorable herpes signal; conflicting results exist. It does not replace antivirals or verify injectable blends.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A small older trial with 52 completers reported a favorable herpes signal; conflicting results exist. It does not replace antivirals or verify injectable blends.
A small older trial with 52 completers reported a favorable herpes signal; conflicting results exist. It does not replace antivirals or verify injectable blends.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis.
1000 mg · Amount per administration
- Frequency
- Three times/day
- Duration
- 6 months
- Route
- Oral
- Context
- Older herpes trial; 52 completers; results not uniform across studies.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID3115841 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Dietary/supplement exposure does not automatically define parenteral or renal-disease safety; context/formulation need separate assessment.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Lysine · 281 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06991738 · 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid CancerRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT06379217 · NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Registry status: Active, not recruitingLast update posted: October 15, 2026Query verification: October 16, 2026
NCT07682649 · Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerRegistry status: Not yet recruitingLast update posted: October 15, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-LYSINE
October 16, 2026
- PMID3115841
Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A.
October 16, 2026
- PMID6419679
Failure of lysine in frequently recurrent herpes simplex infection. Treatment and prophylaxis.
DiGiovanna JJ, Blank H.
October 16, 2026
- SEARCH-PUBMED-lysine
PubMed/MED targeted search: TITLE_ABS:lysine AND TITLE_ABS:"herpes simplex" AND TITLE_ABS:trial
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026